Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum

Wanwisa Dejnirattisai, Robert H Shaw, Piyada Supasa, Chang Liu, Arabella SV Stuart, Andrew J Pollard, Xinxue Liu, Teresa Lambe, Derrick Crook, Dave I Stuart, Juthathip Mongkolsapaya, Jonathan S Nguyen-Van-Tam, Matthew D Snape, Gavin R Screaton, the Com-COV2 study group
doi: https://doi.org/10.1101/2021.12.10.21267534
Wanwisa Dejnirattisai
1Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
2Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert H Shaw
3Oxford Vaccine Group, Department of Paediatrics, University of Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Piyada Supasa
1Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chang Liu
1Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
2Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arabella SV Stuart
3Oxford Vaccine Group, Department of Paediatrics, University of Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew J Pollard
3Oxford Vaccine Group, Department of Paediatrics, University of Oxford
4NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinxue Liu
3Oxford Vaccine Group, Department of Paediatrics, University of Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa Lambe
2Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK
3Oxford Vaccine Group, Department of Paediatrics, University of Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derrick Crook
4NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, University of Oxford, Oxford, UK
5Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dave I Stuart
1Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
2Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK
6Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK
7Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK
8Instruct-ERIC, Oxford House, Parkway Court, John Smith Drive, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juthathip Mongkolsapaya
1Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
2Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK
9Siriraj Center of Research Excellence in Dengue & Emerging Pathogens, Dean Office for Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan S Nguyen-Van-Tam
10Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew D Snape
3Oxford Vaccine Group, Department of Paediatrics, University of Oxford
4NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: matthew.snape@paediatrics.ox.ac.uk
Gavin R Screaton
1Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK
2Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

In this report, we present live neutralisation titres against SARS-CoV-2 Omicron variant, compared with neutralisation against Victoria, Beta and Delta variants. Sera from day-28 post second-dose were obtained from participants in the Com-COV2 study who had received a two-dose COVID-19 vaccination schedule with either AstraZeneca (AZD1222) or Pfizer (BNT162b2) vaccines. There was a substantial fall in neutralisation titres in recipients of both AZD1222 and BNT16b2 primary courses, with evidence of some recipients failing to neutralise at all. This will likely lead to increased breakthrough infections in previously infected or double vaccinated individuals, which could drive a further wave of infection, although there is currently no evidence of increased potential to cause severe disease, hospitalization or death.

Competing Interest Statement

G.R.S sits on the GSK Vaccines Scientific Advisory Board and is a founder member of RQ Biotechnology. MDS acts on behalf of the University of Oxford as an investigator on studies funded or sponsored by vaccine manufacturers, including AstraZeneca, GlaxoSmithKline, Pfizer, Novavax, Janssen, Medimmune, and MCM Vaccines. He receives no personal financial payment for this work. AJP reports grants from UKRI, CEPI and NIHR, during the conduct of the study. AJP is Chair of DHSCs Joint Committee on Vaccination & Immunisation (JCVI), but does not participate in discussions on COVID19 vaccines, and is a member of the WHOs SAGE. The views expressed in this article are those of the authors and do not necessarily represent the views of DHSC, JCVI, NIHR or WHO. The University of Oxford has entered into a partnership with AstraZeneca for the development of a coronavirus vaccine. JSN-V-T is seconded to the Department of Health and Social Care, England (DHSC). The views expressed in this manuscript are those of its authors and not necessarily those of DHSC.

Clinical Trial

ISRCTN27841311 ISRCTN webpage: https://www.isrctn.com/ISRCTN27841311?q=27841311&filters=&sort=&offset=1&totalResults=1&page=1&pageSize=10&searchType=basic-search

Clinical Protocols

https://comcovstudy.org.uk/study-protocol

Funding Statement

The work was supported by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant number: 2018-I2M-2-002) to DIS and GRS, DIS by the UKRI MRC (MR/N00065X/1). DIS and GRS are Jenner Investigators. The Wellcome Centre for Human Genetics is supported by the Wellcome Trust (grant 090532/Z/09/Z). Com-COV2 was funded by the UK Government through the National Institute for Health Research (NIHR), the Vaccine Task Force (VTF) and the Coalition for Epidemic Preparedness Innovations (CEPI). This research was supported by the NIHR Oxford Biomedical Research Centre, NIHR Guy's and St Thomas' Biomedical Research Centre, NIHR King's Clinical Research Facility and NIHR Policy Research Programme (PR-R17-0916-22001), the Southampton NIHR Biomedical Research Centre and Southampton NIHR Clinical Research Facility and delivered through the NIHR-funded National Immunisation Schedule Evaluation Consortium (NISEC). NVX-CoV2373 vaccine was supplied for use in Com-COV2 by Novavax, Inc. MDS and AJP are Jenner Investigators and NIHR Senior Investigators and supported by the Oxford NIHR Biomedical Research Centre.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The South Central - Berkshire Research Ethics Committee gave ethical approval for this work. Reference 21/SC/0119.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵# joint senior author

Data Availability

Upon requests directed to the corresponding author, after approval of a proposal, data can be shared through a secure online platform.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted December 11, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum
Wanwisa Dejnirattisai, Robert H Shaw, Piyada Supasa, Chang Liu, Arabella SV Stuart, Andrew J Pollard, Xinxue Liu, Teresa Lambe, Derrick Crook, Dave I Stuart, Juthathip Mongkolsapaya, Jonathan S Nguyen-Van-Tam, Matthew D Snape, Gavin R Screaton, the Com-COV2 study group
medRxiv 2021.12.10.21267534; doi: https://doi.org/10.1101/2021.12.10.21267534
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum
Wanwisa Dejnirattisai, Robert H Shaw, Piyada Supasa, Chang Liu, Arabella SV Stuart, Andrew J Pollard, Xinxue Liu, Teresa Lambe, Derrick Crook, Dave I Stuart, Juthathip Mongkolsapaya, Jonathan S Nguyen-Van-Tam, Matthew D Snape, Gavin R Screaton, the Com-COV2 study group
medRxiv 2021.12.10.21267534; doi: https://doi.org/10.1101/2021.12.10.21267534

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (500)
  • Anesthesia (110)
  • Cardiovascular Medicine (1226)
  • Dentistry and Oral Medicine (205)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (527)
  • Epidemiology (9991)
  • Forensic Medicine (5)
  • Gastroenterology (496)
  • Genetic and Genomic Medicine (2430)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1632)
  • Health Policy (750)
  • Health Systems and Quality Improvement (632)
  • Hematology (247)
  • HIV/AIDS (529)
  • Infectious Diseases (except HIV/AIDS) (11842)
  • Intensive Care and Critical Care Medicine (623)
  • Medical Education (250)
  • Medical Ethics (73)
  • Nephrology (267)
  • Neurology (2266)
  • Nursing (139)
  • Nutrition (349)
  • Obstetrics and Gynecology (449)
  • Occupational and Environmental Health (532)
  • Oncology (1241)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (154)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (727)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (280)
  • Psychiatry and Clinical Psychology (2272)
  • Public and Global Health (4814)
  • Radiology and Imaging (832)
  • Rehabilitation Medicine and Physical Therapy (486)
  • Respiratory Medicine (650)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (224)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (123)
  • Urology (99)